Trials / Completed
CompletedNCT00150202
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
Clinical Study Of EYE001 In Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium |
Timeline
- Start date
- 2004-07-01
- Completion
- 2006-10-01
- First posted
- 2005-09-08
- Last updated
- 2007-05-07
Locations
14 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00150202. Inclusion in this directory is not an endorsement.